Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Enoxaparin yields superior net clinical benefit to UFH in subjects undergoing PCI for STEMI

Sep. 17, 2010

Lundbeck and Argenta disclose promising preclinical data on MCH1 receptor antagonists

Sep. 17, 2010

RAAM-DHF trial finds eplerenone may benefit patients with diastolic heart failure

Sep. 17, 2010

PAF-R is potential target to treat psoriasis

Sep. 17, 2010

GSK presents new prostanoid DP1 receptor antagonists

Sep. 16, 2010

New fatty-acid amide hydrolase 1 inhibitor JNJ-40355003 has preclinical analgesic effects

Sep. 16, 2010

BT-061 improves psoriasis in double-blind trial

Sep. 16, 2010

Cypher sirolimus-eluting stent superior to Endeavor zotarolimus-eluting stent in phase III trial

Sep. 16, 2010

Clinical data support potential of rufinamide for neuropathic pain

Sep. 16, 2010

Promising phase Ib/IIa data on OBP-601 in HIV

Sep. 15, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.